PapersPMID:25686270
Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors.
- findings
- 4
- compound
- 1
- endpoints
- 4
- Study, every finding
- meta-analysis
- Dose studied, every finding
- 1.4 g to 3 g per day
- Population, every finding
- Adults with type 2 diabetes mellitus; pooled from two placebo-controlled trials
No finding here moved its endpoint.
What did not
How to read these marks →“Results from two studies showed that G lucidum was not associated with statistically or clinically significant reduction in HbA1c (WMD -0.10%; 95% CI -1.05% to 0.85%; 130 participants), total cholesterol (WMD -0.07mmol/L; 95% CI -0.57 mmol/L to 0.42 mmol/L; 107 participants ), low-density lipoprotein cholesterol (WMD 0.02 mmol/L; 95% CI -0.41 mmol/L to 0.45 mmol/L; 107 participants), or body-mass index (WMD -0.32 kg/m(2); 95% CI -2.67 kg/m(2) to 2.03 kg/m(2;) 107 participants).”
- Participants
- 130
- Effect
- −0.1 mean difference, 95% CI −1.05 to 0.85
- No detected effect on LDL cholesterol
very limited
- Participants
- 107
- Effect
- 0.02 mean difference, 95% CI −0.41 to 0.45
- No detected effect on body mass index
very limited
- Participants
- 107
- Effect
- −0.32 mean difference, 95% CI −2.67 to 2.03
- No detected effect on total cholesterol (TC)
very limited
- Participants
- 107
- Effect
- −0.07 mean difference, 95% CI −0.57 to 0.42
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adults with type 2 diabetes mellitus (three studies used for statistical analyses); Ganoderma lucidum for cardiovascular risk factors
- Participants
- 398
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 10